Citi Raises PT On ENDP

Citi has raised its price target from $42 to $48 on Endo Pharmaceuticals Holdings

, after meeting with the company's senior management to discuss the ENDP acquisition of American Medical Systems. Says Citi, in its report, “The most underappreciated aspects of AMS transaction are its: 1) diversification, 2) high sales growth, 2) high urology market shares, & 4) expansion into ex-US markets.” Citi maintains its Buy rating on the stock. ENDP closed at$39.93 yesterday.